Genomic & Biopharma NewsPalm Beach Post: ORB Leaves Palm Beach County for New Lab Space
David Willoughby lives in Palm Beach Gardens and, until recently, worked there too. But the owner of Ocean Ridge Biosciences wanted to expand, and he couldn't find suitable space in northern Palm Beach County. Please read the PDF for more details
|ORB Company News, 2016-12-02 15:35:33|
Tyto Care nets CE mark for digital, at-home doctor’s exams
Telehealth developer Tyto Care has received a CE mark for its remote medical examination system, including a hand-held digital stethoscope and otoscope for checking the heart, lungs, ears, nose and throat.
|Fierce Biotech, 2018-10-17 15:08:27|
U.K. fights EpiPen shortage by extending injector expiry dates
As a shortage of epinephrine pens continues to grip the U.K., authorities have agreed to extend the expiration date on a second injector to help ease the situation.
|Fierce Pharma, 2018-10-17 15:05:59|
Minnesota AG targets Sanofi, Eli Lilly and Novo Nordisk in latest insulin pricing attack
In a lawsuit this week, Minnesota attorney general Lori Swanson alleged that insulin list prices hikes are "deceptive" and have hurt uninsured and underinsured patients with diabetes. She's asking for injunctive and monetary relief.
|Fierce Pharma, 2018-10-17 14:58:22|
Pelican Newspaper: Gene profiling at Ocean Ridge Biosciences to unlock mysteries of the human body
Identifying the markers for pancreatic cancer may have happened here in a 5,400 square foot facility where scientists routinely practice next generation RNA profiling and biomarker discovery. Please read the PDF for more details
|ORB Company News, 2016-11-25 18:55:37|
Even in worst-case scenario, Roche will grow past biosimilar erosion in the U.S.: executive
Roche’s trio of megablockbuster cancer drugs, Herceptin, Rituxan and Avastin, are expected to face copycats in the U.S. in 2019, but a bullish management team said Wednesday that sales will grow "even in a worst-case scenario," thanks to new drugs like multiple sclerosis star Ocrevus.
|Fierce Pharma, 2018-10-17 14:52:14|
Study shows crabs larval differences are unrelated to their mothers' sizes
Like people, blue crabs aren't all the same sizes and shapes. Now Rutgers scientists have discovered substantial differences in the body structures of larval crab siblings and among larvae from different mothers.
|News Medical Life Sciences, 2018-10-17 14:44:48|
Grants awarded to Russian scientists for new research projects in natural sciences
The employees of the Institute of Natural Sciences and Mathematics Dmitry Zaitsev and Dmitry Tsvetkov and a specialist from the Institute of Chemical Engineering, Tatyana Kalinina won the contest for the best youth teams' scientific project.
|News Medical Life Sciences, 2018-10-17 14:34:18|
New pragmatic study launched to understand the effectiveness of new type 2 diabetes drug
HealthCore, Inc., the outcomes research subsidiary of Anthem, Inc. and Novo Nordisk Inc., which manufacturers the once weekly GLP-1 receptor agonist Ozempic (semaglutide), are working together to launch the first of its kind pragmatic study to understand the benefits of semaglutide as compared with all other available diabetes drugs in a real-world pragmatic clinical trial for Type 2 diabetes - one of the nation's fastest growing chronic diseases.
|News Medical Life Sciences, 2018-10-17 14:27:08|
Patients once thought incurable can benefit from high-dose radiation therapy
In the first randomized, phase II clinical trial of its kind, researchers have shown that an aggressive form of high-precision radiation therapy can greatly increase how long oligometastatic patients live and doubles how long they live without cancer.
|News Medical Life Sciences, 2018-10-17 14:18:27|
FDA puts Affimed's T cell engager on official clinical hold
Just a week after Affimed decided to put its T cell engager for blood cancers on hold, the company reported that the FDA has “concurred with Affimed’s decision to stop recruitment” and placed the program on full clinical hold.
|Fierce Biotech, 2018-10-17 14:15:19|